NEW
YORK, July 28, 2023 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action
lawsuit has commenced on behalf of shareholders of BioXcel
Therapeutics, Inc. (NASDAQ: BTAI).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/bioxcel-class-action-loss-submission-form/?id=42674&from=4
The lawsuit seeks to recover losses for shareholders who
purchased BioXcel between December 15,
2021 and June 28, 2023.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
September 5, 2023 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
According to a filed complaint, BioXcel Therapeutics, Inc.
issued materially false and/or misleading statements and/or failed
to disclose that: (1) the Company lacked adequate internal controls
over protocol adherence and data integrity; (2) as a result, the
Company's principal investigator failed to adhere to the informed
consent form approved by the Institutional Review Board; (3) the
Company's principal investigator failed to maintain adequate case
histories for certain patients whose records were reviewed by the
FDA; (4) the Company's principal investigator fabricated email
correspondence with a pharmacovigilance safety vendor that was then
provided to the FDA; (5) the foregoing would negatively impact the
Company's ability to obtain regulatory approval of BXCL501 for the
treatment of agitation associated with dementia in patients with
probable Alzheimer's disease; and (6) as a result of the foregoing,
defendants' positive statements about the Company's business,
operations, and prospects were materially misleading and/or lacked
a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/btai-shareholder-alert-jakubowitz-law-reminds-bioxcel-shareholders-of-a-lead-plaintiff-deadline-of-september-5-2023-301887880.html
SOURCE Jakubowitz Law